Ignite Creation Date:
2024-05-05 @ 5:15 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00412893
Status:
COMPLETED
Last Update Posted:
2019-04-05
First Post:
2006-12-18
Brief Title:
Isavuconazole BAL8557 for Primary Treatment of Invasive Aspergillosis
Sponsor:
Astellas Pharma Inc
Organization:
Astellas Pharma Inc
Study Overview
Official Title:
A Phase III Double Blind Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused by Aspergillus Species or Other Filamentous Fungi
Status:
COMPLETED
Status Verified Date:
2019-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to compare the efficacy and safety of isavuconazole versus voriconazole in the treatment of patients with invasive aspergillosis
Detailed Description:
Acute invasive fungal infections caused by aspergillus zygomycetes and other filamentous fungi remain life threatening diseases Early treatment with highly effective anti-fungals reduces mortality This study investigates the efficacy and safety of isavuconazole in the treatment of invasive fungal diseases caused by Aspergillus or other filamentous fungi
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2006-003868-59 | EUDRACT_NUMBER | Basilea Protocol ID | None |
| WSA-CS-004 | OTHER | None | None |